Sign Up to like & get
recommendations!
1
Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab073.121
Abstract: Filgotinib (FIL) is a once-daily, oral, preferential Janus kinase 1 inhibitor in development for the treatment of inflammatory bowel disease. FIL for the treatment of moderately to severely active ulcerative colitis (UC) was evaluated in…
read more here.
Keywords:
maintenance study;
maintenance;
fil 200;
study ... See more keywords